EUVIMEDEUVIMED entdecken
Crossref

Gene Therapy Products Reached to Market by 2021

Sümbül Yıldırım, Fatih Kocabaş

Gene Editing · 2021

DOI: 10.29228/genediting.54101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gene Editing, 2021. Verfasst von Sümbül Yıldırım und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vitravene (Fomivirsen) was the first gene silencing antisense oligonucleotide therapy authorized by the FDA in 1998 and the EMEA in 1999.It was created in conjunction with Isis Pharmaceuticals and Novartis Ophthalmics for the treatment of cytomegalovirus (CMV) retinitis patients [5].Abstract: Cell and gene therapy are targeted treatments for genetic illnesses that reduce life quality and shorten lifespan.Cell and gene therapy differ from traditional treatments in that they directly target the malfunctioning gene and can cure it in a single dose.Approvals for cell and gene therapy products have increased rapidly in recent years, particularly since 2017, and investment in this sector has increased.When we look at it, cell and gene therapy products continue to be the most expensive pharmaceuticals.The high cost of R&D technologies, the length of regulatory processes, and the difficulties of mass manufacturing are some of the causes of this high cost.The cell and gene therapy product market, which was $11.9 billion in 2021, is expected to reach $43.7 billion by 2024.This target is dependent on the FDA's announcement that it expects to approve 10-20 new cell and gene therapy products per year until 2025.We have compiled a list of 25 gene therapy products that have been approved by any institution through 2021.Some of these products were withdrawn from the market after they were launched for various reasons, which we have also mentioned here.

Zitieren

APA

Yıldırım, S., & Kocabaş, F. (2021). Gene Therapy Products Reached to Market by 2021. Gene Editing. https://doi.org/10.29228/genediting.54101

Vancouver

Yıldırım S, Kocabaş F. Gene Therapy Products Reached to Market by 2021. Gene Editing. 2021. doi:10.29228/genediting.54101

BibTeX
@article{Yldrm2021,
  author = {Yıldırım, Sümbül and Kocabaş, Fatih},
  title = {Gene Therapy Products Reached to Market by 2021},
  journal = {Gene Editing},
  year = {2021},
  doi = {10.29228/genediting.54101}
}
Kostenlos starten →